Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/25/2010CA2368621C Methods and compositions for treating solid tumors
05/25/2010CA2362279C Connective tissue softening
05/25/2010CA2362273C Benzazepine-n-ethanoic acid derivatives for treating secondary hypertension
05/25/2010CA2326874C Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions
05/25/2010CA2322424C 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them
05/25/2010CA2321920C 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
05/25/2010CA2315886C Process for the production of epigallocatechin gallate
05/25/2010CA2314156C Pyrrole substituted 2-indolinone protein kinase inhibitors
05/25/2010CA2310147C Spheroids, preparation method and pharmaceutical compositions
05/25/2010CA2307028C Medicinal uses of phenylalkanols and derivatives
05/25/2010CA2290805C Powdered sorbitol and its preparation
05/25/2010CA2282917C Pulverulent rubber powders comprising modified fillers, processes for their preparation and their use
05/25/2010CA2273917C 3-pyridyl enantiomers and their use as analgesics
05/25/2010CA2265046C Biocidal compositions
05/25/2010CA2245890C Use of an extract of cimicifuga racemosa
05/25/2010CA2223837C Aav transduction of myoblasts
05/25/2010CA2199715C Novel implant and novel vector for the treatment of acquired diseases
05/20/2010WO2010057217A1 Compositions and methods for increasing cellular uptake of rnai via sid-1
05/20/2010WO2010057197A1 Cancer vaccine compositions and methods of using the same
05/20/2010WO2010057150A1 Releasable polymeric lipids for nucleic acids delivery systems
05/20/2010WO2010057141A2 Alphavirus inhibitors and uses thereof
05/20/2010WO2010057126A1 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
05/20/2010WO2010057121A1 Pyrazine compounds as phosphodiesterase 10 inhibitors
05/20/2010WO2010057118A2 Heterocyclic antagonists of prostaglandin d2 receptors
05/20/2010WO2010057104A2 Pyridoindole modulators of nmda receptor and acetylcholinesterase
05/20/2010WO2010057101A2 Compounds useful as hiv blockers
05/20/2010WO2010057088A2 Pyrrolidinyl modulators of nicotinic acetylcholine receptors
05/20/2010WO2010057084A1 Method of treating ischemia reperfusion injury
05/20/2010WO2010057080A1 Surface modification of polymers via surface active and reactive end groups
05/20/2010WO2010057066A1 Pharmacokinetically-based dosing regimens of a thrombin receptor antagonist
05/20/2010WO2010057048A1 Therapies for hematologic malignancies
05/20/2010WO2010057047A1 Cd37 immunotherapeutic combination therapies and uses thereof
05/20/2010WO2010057036A2 Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
05/20/2010WO2010057034A1 Compositions and methods for alleviating hyposalivation and for providing oral comfort
05/20/2010WO2010057028A2 Treatment of proteinopathies using a farnesyl transferase inhibitor
05/20/2010WO2010057020A2 Modification of amyloid-beta load in non-brain tissue
05/20/2010WO2010057006A1 Azaquinolinone derivatives and uses thereof
05/20/2010WO2010057000A2 Neuraminidase inhibitors and uses thereof
05/20/2010WO2010056985A2 Treatment of proteinopathies using a farnesyl transferase inhibitor
05/20/2010WO2010056979A1 Phenothiazine derivatives for treatment of asthma
05/20/2010WO2010056941A1 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
05/20/2010WO2010056939A1 Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
05/20/2010WO2010056927A1 Chitosan derivatives alone or in combination for the treatment of mdr microbial infections
05/20/2010WO2010056919A2 Eflornithine prodrugs, conjugates and salts, and methods of use thereof
05/20/2010WO2010056914A1 Bacterial helicase inhibitor compounds and uses thereof
05/20/2010WO2010056910A2 Methods of treating cardiovascular disorders
05/20/2010WO2010056907A2 Compounds that induce pancreatic beta-cell expansion
05/20/2010WO2010056896A1 Chitosan derivatives to treat animals or optimize animal health
05/20/2010WO2010056877A2 Haloalkyl containing compounds as cysteine protease inhibitors
05/20/2010WO2010056875A1 Pyridazinones and their use as btk inhibitors
05/20/2010WO2010056872A2 Antimicrobial compositions
05/20/2010WO2010056865A1 Quinoline derivatives as ion channel modulators
05/20/2010WO2010056849A1 Gamma secretase modulators
05/20/2010WO2010056847A2 Lyophilization formulation
05/20/2010WO2010056827A1 Beta-lactamase inhibitors
05/20/2010WO2010056788A1 Anti-hypercholesterolemic compounds
05/20/2010WO2010056767A1 Thiochromene derivatives as hip hydroxylase inhibitors
05/20/2010WO2010056758A1 Quinazoline derivatives as kinase inhibitors
05/20/2010WO2010056754A2 Inhibition of mammalian target of rapamycin
05/20/2010WO2010056746A1 Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
05/20/2010WO2010056741A2 Phenylacetic acid inhibitors of cyclooxygenase
05/20/2010WO2010056737A2 Methods and compositions involving mirnas in cancer stem cells
05/20/2010WO2010056735A1 Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
05/20/2010WO2010056726A1 Compositions and methods for treating diabetes
05/20/2010WO2010056722A1 Gamma secretase modulators
05/20/2010WO2010056717A1 Substituted bicyclic amines for the treatment of diabetes
05/20/2010WO2010056708A1 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
05/20/2010WO2010056677A1 Methods of inhibiting cancer cell growth with hdac inhibitors and methods of screening for hdac10 inhibitors
05/20/2010WO2010056672A2 Butylammonium modulators of fatty acid transport
05/20/2010WO2010056644A1 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS
05/20/2010WO2010056633A2 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
05/20/2010WO2010056630A1 Triazolopyrimidinones and methods of use thereof
05/20/2010WO2010056622A1 TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
05/20/2010WO2010056620A1 Tetrasubstituted pyridazines hedgehog pathway antagonists
05/20/2010WO2010056588A1 Tetrasubstituted pyridazine hedgehog pathway antagonists
05/20/2010WO2010056575A1 P70 s6 kinase inhibitor and egfr inhibitor combination therapy
05/20/2010WO2010056574A1 P70 s6 kinase inhibitor and mtor inhibitor combination therapy
05/20/2010WO2010056567A1 Imidazoisoindole neuropeptide s receptor antagonists
05/20/2010WO2010056564A1 Quinolone neuropeptide s receptor antagonists
05/20/2010WO2010056563A1 Akt and p70 s6 kinase inhibitors
05/20/2010WO2010056549A1 Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
05/20/2010WO2010056527A2 Fused heterocyclic compounds as ion channel modulators
05/20/2010WO2010056413A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION
05/20/2010WO2010056344A1 Substituted dioxopiperidinyl phthalimide derivaties
05/20/2010WO2010056320A2 Pi3k/mtor kinase inhibitors
05/20/2010WO2010056311A1 Pyrazinopyrazines and derivatives as kinase inhibitors
05/20/2010WO2010056309A2 Methods and compositions related to targeting monoacylglycerol lipase
05/20/2010WO2010056230A1 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
05/20/2010WO2010056223A1 Derivatives of hypoestoxides for the treatment of malaria
05/20/2010WO2010056216A1 Pharmaceutical composition comprising ibuprofen, pseudoephedrine and chlorpheniramine
05/20/2010WO2010056205A1 Intravascular contrast agents
05/20/2010WO2010056196A1 New compounds 578
05/20/2010WO2010056195A1 New compounds 575
05/20/2010WO2010056194A1 5h-pyrrolo [ 3, 4-b] pyridin derivatives and their use
05/20/2010WO2010056145A1 Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations
05/20/2010WO2010056113A1 Ophthalmic solutions, including contact lens care solutions and eye drops comprising carnosine, preferably in combination with dexpanthenol and/or hyaluronic acid
05/20/2010WO2010056048A2 Pharmaceutical composition for suppressing dna methyltransferase, containing aryloxyacetyl-based compounds as active ingredients
05/20/2010WO2010056044A2 Novel compound acting as a vanilloid receptor antagonist, isomer or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same
05/20/2010WO2010056041A2 Pharmaceutical composition for treating and preventing heart diseases caused by ischemia or ischemic reperfusion
05/20/2010WO2010056039A2 Oral pharmaceutical formulation of pelubiprofen with improved dissolution rate and stability
1 ... 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 ... 7860